Literature DB >> 2579134

B5, a new B cell-restricted activation antigen.

A S Freedman, A W Boyd, K C Anderson, D C Fisher, S F Schlossman, L M Nadler.   

Abstract

The characterization of a new human B cell-restricted activation antigen (B5) is described in this report. With the use of a monoclonal antibody to B5, we show that B5 can be detected on peripheral blood or splenic B cells after 1 day of stimulation with either anti-immunoglobulin, protein A, Epstein Barr virus, or pokeweed mitogen. In contrast, B5 was not expressed on resting B, T, or myeloid cells. More important, B5 could not be detected on activated T cells or monocytes. The B5 antigen was expressed on some lymphoblastoid B cell lines and B cell neoplasms but was not expressed on leukemias or lymphomas of T or myeloid origin. The B5 antigen is distinct from previously reported B cell activation antigens by its m.w. and pattern of cellular expression. These studies suggest that B5 is a novel B cell-restricted activation antigen, which may be useful to study the events of early human B cell activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579134

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Considering B7-CD28 as a family through sequence and structure.

Authors:  Sean M West; Xiaodi A Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-17

Review 2.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

3.  mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1-transformed T cells.

Authors:  A Vallé; P Garrone; H Yssel; J Y Bonnefoy; A S Freedman; G Freeman; L M Nadler; J Banchereau
Journal:  Immunology       Date:  1990-04       Impact factor: 7.397

Review 4.  Surface antigens associated with human B cell activation.

Authors:  L K Jung
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

5.  Immunophenotypic profile of CNS lymphoma: a review of eighteen cases.

Authors:  R Bashir; A Freedman; N Harris; K Bain; L Nadler; F Hochberg
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

6.  Characterization of the common acute lymphoblastic leukaemia antigen (CD10) as an activation molecule on mature human B cells.

Authors:  N Kiyokawa; Y Kokai; K Ishimoto; H Fujita; J Fujimoto; J I Hata
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

7.  Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines.

Authors:  M Birkenbach; D Liebowitz; F Wang; J Sample; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

Authors:  B D Hock; G C Starling; P B Daniel; D N Hart
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  A 72-kD B cell-associated surface glycoprotein expressed at high levels in hairy cell leukaemia and plasma cell neoplasms.

Authors:  K Pulford; K Micklem; J Thomas; M Jones; D Y Mason
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

10.  A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6.

Authors:  D Buchwald; A S Freedman; D V Ablashi; J L Sullivan; M Caligiuri; D S Weinberg; C G Hall; R L Ashley; C Saxinger; N Balachandran
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.